Federated Hermes’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Federated Hermes’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-8,105	Closed	-$49K	–	2385
2019 Q4	$49K	Buy	+8,105	New	+$55.4K	﹤0.01%	1741
2016 Q1	–	Sell	-450,000	Closed	-$4.53M	–	2190
2015 Q4	$4.53M	Hold	450,000	–	–	0.01%	591
2015 Q3	$6.44M	Buy	+450,000	New	+$11M	0.02%	506

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

PCM

Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Federated Hermes's ZYNE Position: Q1 2020 in Review

Federated Hermes sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2020, closing a stake of 8,105 shares — an estimated $49K sold.

Federated Hermes first reported a position in ZYNE in Q3 2015 and held it in 3 quarters. The position peaked at $6.44M in Q3 2015. 77 funds tracked by Wall St. Rank hold ZYNE as of Q1 2020.

Federated Hermes reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2020 after selling out during the quarter.
Federated Hermes sold 8,105 Zynerba Pharmaceuticals, Inc shares in Q1 2020, an estimated $49K.
Federated Hermes first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 3 quarters.
Federated Hermes's Zynerba Pharmaceuticals, Inc position peaked at $6.44M in Q3 2015.
77 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2020.

Based on Federated Hermes's 13F filing for Q1 2020, filed 13 May 2020.